Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Middle East Conflict Impacts Australia and New Zealand Businesses 
SOUTH SAN FRANCISCO, Calif., May 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
